Search

Carbazochrome

Carbazochrome is a hemostatic agent that promotes clotting, preventing blood loss from open wounds. It is an oxidation product of adrenaline which enhances the microcirculatory tone [A19747].

Zafirlukast

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator.

Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase

It comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV. … Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy.

Chromium nicotinate

Drospirenone

[L7973] Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy. … Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.

Homosalate

Homosalate is an organic compound that belongs to salicylates. It is an ester formed from salicylic acid and 3,3,5-trimethylcyclohexanol, a derivative of cyclohexanol.

alpha-Tocopherol succinate

Most individuals obtain adequate vitamin E intake from their diets; genuine vitamin E deficiency is considered to be rare. … Alpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements.

D-3082-L

D-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.

Isoflurophate

(From Martindale, The Extra Pharmacopoeia, 29th ed, p1330) … An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma.

Raloxifene

[A716] Although rare, there was an increased risk of venous thromboembolism during clinical trials of postmenopausal women receiving raloxifene. … Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation.